Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry J Copeland

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|April 13, 2013
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group studyLisa M Landrum, James Java, Cara A Mathews, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2014
Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 studyRitu Salani, David M O'Malley, Larry J Copeland, et al.
Gynecologic Oncology|December 17, 2003
Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?Jaina Lindauer, Jeffrey M Fowler, Tom P Manolitsas, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 14, 2009
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancerLeigh G Seamon, Matthew J Carlson, Debra L Richardson, et al.
American Journal of Obstetrics and Gynecology|April 25, 2003
Pre-emptive analgesia in gynecologic surgical procedures: preoperative wound infiltration with ropivacaine in patients who undergo laparotomy through a midline vertical incisionGlenn M Updike, Tom P Manolitsas, David E Cohn, et al.
Gynecologic Oncology|September 5, 2008
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapyDebra L Richardson, Leigh G Seamon, Matthew J Carlson, et al.
Gynecologic Oncology|January 24, 2016
Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMICaroline C Billingsley, Catherine Cansino, David M O'Malley, et al.
Gynecologic Oncology|February 16, 2010
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancerKimberly E Resnick, Wendy L Frankel, Carl D Morrison, et al.
The New England Journal of Medicine|January 6, 2006
Intraperitoneal cisplatin and paclitaxel in ovarian cancerDeborah K Armstrong, Brian Bundy, Lari Wenzel, et al.
Gynecologic Oncology|October 3, 2008
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancerDebra L Richardson, Floor J Backes, Leigh G Seamon, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|April 13, 2013
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group studyLisa M Landrum, James Java, Cara A Mathews, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2014
Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 studyRitu Salani, David M O'Malley, Larry J Copeland, et al.
Gynecologic Oncology|December 17, 2003
Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?Jaina Lindauer, Jeffrey M Fowler, Tom P Manolitsas, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 14, 2009
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancerLeigh G Seamon, Matthew J Carlson, Debra L Richardson, et al.
American Journal of Obstetrics and Gynecology|April 25, 2003
Pre-emptive analgesia in gynecologic surgical procedures: preoperative wound infiltration with ropivacaine in patients who undergo laparotomy through a midline vertical incisionGlenn M Updike, Tom P Manolitsas, David E Cohn, et al.
Gynecologic Oncology|September 5, 2008
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapyDebra L Richardson, Leigh G Seamon, Matthew J Carlson, et al.
Gynecologic Oncology|January 24, 2016
Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMICaroline C Billingsley, Catherine Cansino, David M O'Malley, et al.
Gynecologic Oncology|February 16, 2010
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancerKimberly E Resnick, Wendy L Frankel, Carl D Morrison, et al.
The New England Journal of Medicine|January 6, 2006
Intraperitoneal cisplatin and paclitaxel in ovarian cancerDeborah K Armstrong, Brian Bundy, Lari Wenzel, et al.
Gynecologic Oncology|October 3, 2008
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancerDebra L Richardson, Floor J Backes, Leigh G Seamon, et al.
Pageof 11